Compare Gilead Sciences, Inc. (GILD) vs T Rowe Price Group Inc (TROW) Price & Performance

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

T. Rowe Price (TROW) trades at $114.02, up 0.35% today, with a neutral technical outlook and mixed analyst sentiment. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51, driven by record assets under management and higher advisory fees. The stock trades at a P/E of 11.45, below industry averages, indicating potential undervaluation. Dividend payments remain stable at $1.30 per share, supporting income investors.

Outlook is cautiously optimistic given strong profitability metrics like a 29.26% net income margin and 20.1% ROE, but risks include expense pressures and net outflows. Analyst consensus price target is $112.17, slightly below current price, with 63% hold ratings suggesting limited near-term upside. Investors should weigh solid fundamentals against competitive headwinds in the asset management sector.